Tirzepatide is a controlled medication in New Zealand approved by Medsafe for treating type-2 diabetes or obesity
This means at least 30 minutes before a meal or 2 hours after
Trial evidence: Tesamorelin 2mg SC daily sustained GH/IGF-1 elevation, 15-18% visceral fat reduction over 6 months (Falutz, NEJM 2007, PMID 17699044) Ipamorelin 200-300 mcg peak GH 5-10x baseline within 30 minutes, no cortisol/prolactin bump (Raun, EJE 1998, PMID 9539826) GHRH + GHRP synergy 2-3x greater amplitude than either alone (Bowers, JCEM 1991, PMID 2004615) Community protocols extend this evidence base with cycling patterns that weren't studied in the original trials the 5-on/2-off rhythm and 8-week cycles are empirical community consensus, not clinically validated
Tesamorelin is not FDA-approved as a general treatment for obesity or routine weight loss
Due to potential physical and psychological side effects, any GLP-1 use should be medically monitored
Therefore, in this context, free heme toxicity would be mitigated
